Candel Therapeutics (CADL) vs Odyssey Therapeutics (ODTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Odyssey Therapeutics is the larger company by market cap ($913.1 million vs $760.6 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CADL | ODTX |
|---|---|---|
| Share price | $9.94 | $19.00 |
| Market cap | $760.59M | $913.11M |
| 1-day change | +2.90% | +4.86% |
| YTD return | +75.93% | — |
| 1-year return | +51.76% | — |
| 5-year return | +1.12% | — |
| EPS (TTM) | $-1.50 | $-7.92 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $14.00 | $29.05 |
| 52-week low | $4.35 | $15.10 |
| Distance from 52-week high | -29.00% | -34.60% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +118.81% | +88.16% |
| Average volume | 1.21M | 269.30K |
| Shares outstanding | 76.52M | 48.06M |
| Employees | 55 | 100 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Candel Therapeutics
CADL stock →Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC).
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 55 employees
About Odyssey Therapeutics
ODTX stock →Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company pipeline includes OD-001, an oral small molecule inhibitor of receptor-interacting protein kinase 2, which is in phase 2a trial for the treatment of ulcerative colitis; OD-002, an oral small molecule SLC15A4 inhibitor designed to block TLR7/8/9-mediated pathogenic inflammatory responses activation of interferon regulatory factor 5 (IRF5); OD-003, a protein therapeutic designed to agonize tumor necrosis factor receptor 2 selectively on Treg; a TSLP/IL-33 bispecific antagonist; an oral small molecule interleukin-1 receptorassociated kinase 4 scaffolding inhibitor; and a small molecule inhibitor of IRF5.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 100 employees
CADL vs ODTX FAQ
Which is bigger, Candel Therapeutics or Odyssey Therapeutics?
Odyssey Therapeutics (ODTX) is larger, with a market capitalization of $913.11M compared with $760.59M for Candel Therapeutics (CADL).
Are Candel Therapeutics and Odyssey Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.